drugset
drugset / Trial / NCT04200755

Clinical Trial to Evaluate Efficacy and Safety of Dupilumab in Localized Scleroderma

NCT04200755 ↗

Phase 2 Completed 45 enrolled University of Cologne
RandomizedParallel-groupDouble-blindTreatment

Summary

The DupiMorph study evaluates the efficacy of Dupilumab in localized scleroderma patients. Dupilumab is approved in the US and EU for the treatment of moderate/severe atopic dermatitis and since 2018 in the US for severe asthma therapy.

Timeline

Start
2020-05-19
Primary completion
2023-11-30
Completion
2023-11-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Dupilumab Monoclonal antibody 300 mg Subcutaneous

Indications

localized scleroderma